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ABSTRACT
Guidelines for the prevention and treatment of venous thromboembolism (VTE) are aimed to improve patients’ 
safety and quality of life by appropriate prophylaxis and treatment of deep venous thrombosis (DVT) and pul-
monary embolism (PE).
These guidelines relate to adult cancer patients treated non-surgically. Recommendations included in those 
guidelines do not relate to paediatric patients.
The guidelines presented here directed to physicians and other healthcare professionals taking care of mentioned 
patients: clinical oncologists, haematologists, radiotherapists, pulmonologists, oncological gynaecologists, internal 
medicine physicians, and GPs.
•	Venous	thromboembolism	(VTE)	comprises	a	serious	problem	in	oncology	because	it	is	the	most	common	
complication as well as the second most common cause of cancer-related deaths. 
•	 the	term	“venous	thromboembolism”	includes	the	cases	of	DVT	and	PE;	however,	the	former	is	a	primary	event	
and the latter is a secondary result.
•	Active	malignant	disease	classifies	patients	to	a	group	with	at	least	moderate	risk	of	VTE.
•	D-dimer	levels	could	be	increased	in	cancer	patients	without	concomitant	VTE.	
•	D-dimer	levels	below	cut-off	value	(negative	D-dimer)	do	not	exclude	VTE	in	cancer	patients.	
•	 In	patients	with	active	malignant	disease	with	clinical	symptoms	suggesting	VTE	ultrasound	(US)	examina-
tion of deep veins or computed tomography angiography (angio-CT) should be performed, depending on 
the symptoms.
•	Low-molecular-weight	heparins	(LMWH)	are	the	drugs	of	choice	in	prevention	and	treatment	of	VTE	in	cancer	
patients. 
•	Antithrombotic	treatment	in	cancer	patients	with	DVT	does	not	differ	from	treatment	of	cancer	patients	with	PE,	
except clear indications to thrombolytic therapy. 
•	Cancer	patients	with	clinical	symptoms	suggesting	PE	(dyspnoea,	chest	pain	or	tachycardia)	are	per	definition	
classified	into	the	group	of	moderate	or	high	clinical	probability	of	PE.
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•	The	majority	of	PE	cases	account	for	embolism,	which	do	not	warrant	thrombolytic	treatment	and	should	be	
treated	with	LMWH,	UFH,	or	fondaparinux;	LMWHs	are	the	treatment	of	choice	in	cancer	patients	with	VTE.
•	Cancer	patients	have	increased	risk	of	recurrence	of	VTE.
•	Available	evidence	does	not	justify	the	use	of	antithrombotic	drugs	to	prolong	survival	in	cancer	patients.
Key words: venous thromboembolism, deep vein thrombosis, pulmonary embolism, cancer patients, prophylaxis, 
treatment,	low-molecular-weight	heparin,	PE,	VTE,	DVT,	LMWH
Oncol Clin Pract	2016;	12,	3:	67–91
Content
Abbreviations, explanations, and terminology used in this publication ................................................................. 69
General part .................................................................................................................................................................. 69
1. Introduction  ........................................................................................................................................................... 69
2. Venous thromboembolism (VTE)......................................................................................................................... 70
 2.1. Complications of VTE  .................................................................................................................................... 70
 2.2. Diagnosis of VTE ............................................................................................................................................. 71
 2.3. Prevention of VTE ........................................................................................................................................... 71
 2.4. Treatment of cancer patients with VTE ........................................................................................................ 71
 2.5. Antithrombotic drugs in prevention and treatment of patients with VTE  ................................................ 71
  2.5.1. Low-molecular-weight heparin (LMWH) administered subcutaneously (s.c.) ............................... 71
  2.5.2. Unfractionated heparin (UFH) ........................................................................................................... 71
  2.5.3. Fondaparinux  ........................................................................................................................................ 71
  2.5.4. Vitamin K antagonists (VKA) (acenocoumarol and warfarin) ........................................................ 72
  2.5.5. Direct oral anticoagulants (DOAC) .................................................................................................... 72
 2.6. Contradictions to pharmacological antithrombotic treatment .................................................................... 72
 2.7. Non-pharmacological methods for antithrombotic prevention ................................................................... 72
 2.8. Thrombolytic drugs  ......................................................................................................................................... 72
 2.9. Contradictions to thrombolytic drugs according to 2014 European Society of Cardiology guidelines ... 73
Detailed part  ................................................................................................................................................................. 73
3. Risk factors, symptoms, forms, and diagnosis of VTE ........................................................................................ 73
 3.1. Patient-related risk factors of VTE  ............................................................................................................... 73
 3.2. Cancer-related risk factors of VTE ................................................................................................................ 73
 3.3. Treatment-related risk factors of VTE .......................................................................................................... 73
  3.3.1. Chemotherapy ......................................................................................................................................... 73
  3.3.2. Hormone therapy .................................................................................................................................... 74
  3.3.3. Anti-angiogenic treatment ..................................................................................................................... 74
  3.3.4. Radiotherapy ........................................................................................................................................... 74
 3.4. Symptoms and forms of VTE .......................................................................................................................... 75
  3.4.1. Lower extremities VTE .......................................................................................................................... 75
  3.4.2. Upper extremities VTE .......................................................................................................................... 75
  3.4.3. Pulmonary embolism (PE) ..................................................................................................................... 75
  3.4.4. Migratory thrombophlebitis (Trousseau syndrome) ............................................................................ 75
  3.4.5. Marantic endocarditis ............................................................................................................................. 75
  3.4.6. Hepatic vein thrombosis (Budd-Chiari syndrome) .............................................................................. 75
  3.4.7. Thrombosis in the portal vein, splenic vein, mesenteric vein, and renal veins .................................. 75
  3.4.8. Incidental VTE ........................................................................................................................................ 75
 3.5. Diagnosis  .......................................................................................................................................................... 75
 3.6. Searching for cancer in patients with VTE or PE — occult malignancy .................................................... 76
4. Prevention of VTE in patients with cancers treated non-surgically ................................................................... 76
 4.1. Prevention of VTE in hospitalised, medically ill cancer patients ................................................................ 76
 4.2. Prevention of VTE in outpatients undergoing non-surgical anticancer treatment ................................... 77
 4.3. Antithrombotic prevention in patients with indwelling central venous catheter ....................................... 78
 4.4. Prevention of VTE in patients with concomitant thrombocytopaenia ....................................................... 78
 4.5. Antithrombotic prevention in patients with concomitant renal insufficiency  ........................................... 79
 4.6. Antithrombotic prevention in terminally ill cancer patients treated in hospices ....................................... 79
 4.7. Prevention of VTE in pregnant women diagnosed with cancer .................................................................. 79
69
Marek Z. Wojtukiewicz et al., Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients
5. Treatment of cancer patients with VTE ............................................................................................................... 80
 5.1. Initial treatment of cancer patients with VTE or PE with no need for thrombolytic therapy ..................80
 5.2. Initial treatment of cancer patients with PE with need for thrombolytic therapy .....................................81
 5.3. Long-term and chronic treatment of cancer patients with VTE  ................................................................82
 5.4. Treatment of cancer patients with VTE and concomitant thrombocytopaenia .........................................85
 5.5. Treatment of cancer patients with VTE and renal insufficiency  ................................................................86
 5.6. Treatment of pregnant women with coincidence of cancer and VTE ........................................................86
 5.7. Treatment of recurrent VTE during antithrombotic treatment ..................................................................87
6. Using of antithrombotic treatment in order to prolong overall survival in cancer patients ............................87
References  ...........................................................................................................................................................88
Abbreviations, explanations, and terminology used in this publication (in alphabetical order)
Angio-CT — computed tomography angiography
Angio-MR — magnetic resonance angiography
Anti-Xa — (activity) inhibiting factor Xa
APTT — activated partial thromboplastin time
ASA — acetylsalicylic acid
ASD — atrial septal defect
BMI — body mass index
b.w. — body weight
CR — complete remission
CRP — C-reactive protein
CT — computed tomography
CVI — chronic venous insufficiency
DOAC — direct oral anticoagulants
DVT — deep venous thrombosis
eGFR — estimated glomerular filtration rate
ESA — erythropoiesis stimulating agents
HITT — heparin-induced thrombocytopenia
i.m. — intramuscular 
INR — international normalised ratio
IU — international unit
IV — intravenously
LMWH — low-molecular-weight heparin
MR — magnetic resonance
OS — overall survival
PE — pulmonary embolism
PESU — graduated compression stockings
PFS — progression free survival
PT — prothrombin time
PTS — post-thrombotic syndrome
PUP — intermittent pneumatic pressure device
RT — radiotherapy 
r-tPA — recombinant tissue plasminogen activators
s.c. — subcutaneously
SK — streptokinase
SVCS — superior vena cava syndrome
US — ultrasound
UFH — unfractionated heparin
VEGF — vascular endothelial growth factor
VKA — vitamin K antagonists
VSD — ventricular septal defect
VTE — venous thromboembolism
General part
1. Introduction
Venous thromboembolism (VTE) comprises a seri-
ous problem in oncology because it is the most com-
mon complication as well as the second most common 
cause of cancer-related deaths [1–5]. The risk of VTE 
is 4–6-fold higher in cancer patients as compare to the 
general population [1–5]. Population-based trials re-
vealed that year-year cumulative incidence of VTE is 
between 0.8–8% [5]. Moreover, VTE is 4–13-fold more 
frequent in patients with advanced cancer compared to 
the patients with early stage cancers [5]. It mainly affects 
patients with brain malignant tumours, pancreatic, lung, 
gastric, endometrial, bladder, and renal cancers [5]. 
Clinical symptoms of VTE are noted in approximately 
30% of pancreatic and lung cancer patients [3, 4]. Of 
note, in cancer patients with VTE the risk of recurrent 
deep venous thrombosis (DVT) and/or pulmonary 
embolism (PE) is three-fold higher than in non-cancer 
patients with VTE [6, 7]. VTE recurrence risk is highest 
during the first few months after cancer diagnosis and 
can continue for many years after the first thrombosis 
episode [5]. During chemotherapy the risk of VTE is 
increased several times as compared with non-cancer 
individuals, especially in patients with pancreatic and 
gastric cancer [5, 8].
It should be added that VTE itself, antithrombotic 
treatment, as well as VTE complications adversely affect 
the quality of life of cancer patients. Additionally, the 
risk of death in cancer patients with VTE is higher than 
in those without such a complication, which results from 
higher cancer aggressiveness and interaction of cancer 
with haemostasis components [7, 9]. It was also noticed 
that in patients with pancreatic cancer treated with 
chemotherapy occurrence of clinically overt VTE was 
associated with worsening of responses and shortening 
of progression-free survival (PFS) and overall survival 
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(OS) [7]. In the group of cancer patients with VTE 
deaths are eight-fold more frequent than in patients with 
VTE during other underlying diseases [7]. It should be 
also highlighted that the risk of VTE in cancer patients 
increases as more co-morbidities occur [3, 4].
Despite the common prevalence of VTE and its 
unfavourable influence on prognosis in cancer patients 
treated non-surgically, this problem is still underesti-
mated by treating physicians [10, 11]. Thereby, inap-
propriate prevention and treatment could be a conse-
quence. There are an increasing number of patients 
with cancer-related VTE, possibly due to higher mean 
age of patients, longer OS resulting from progress 
of anticancer treatment, as well as better diagnostic 
procedures [12]. These are the reasons for Polish 
experts’ and scientific societies’ initiative to develop 
guidelines to help physicians to identify cancer patients 
with increased VTE risk in daily clinical practice, and 
to use optimal prevention and appropriate treatment 
of VTE as needed. For this purpose, available medical 
literature from the last 20 years was analysed, including 
published international and Polish guidelines regard-
ing this topic:
 — ISTH (International Society on Thrombosis and 
Haemostasis) [13, 14];
 — ASCO (American Society of Clinical Oncology) [8, 
15–17];
 — ESMO (European Society for Medical Oncology) 
[18];
 — NCCN (National Comprehensive Cancer Network) 
[19, 20];
 — ACCP (American College of Chest Physicians) 
[21, 22];
 — Polish guidelines [23–25];
 — AIOM (Italian Association of Medical Oncology) 
[26];
 — French National Guidelines [27] and French Na-
tional Federation of Cancer Centres [28];
 — ESC (European Society of Cardiology) [29];
 — International Consensus Statement [30].
The abovementioned guidelines use a grading of 
strength and reliability of evidence associated to a par-
ticular topic based on the GRADE (Grading of Reco-
mmendations Assessment Development and Evalua-
tion Scale) system and ACCP guidelines published in 
2012 and 2016 [31–33]. Guidelines were assessed as 
either strong [1] or weak [2]. The quality of data from 
published studies using EBM (evidence-based medicine) 
rules, being a basis for guidelines, were described and 
marked with a letter (A), (B), or (C). Guidelines marked 
with letter (A) are manly based on randomised clinical 
trials (RCT) with unambiguous results, and further stud-
ies probably will not elicit any changes. The letter (B) 
indicates that further studies could possibly influence the 
changes of guidelines, whilst the letter (C) indicates low 
quality of available data, resulting mainly from scarce 
RCT, so further studies are very likely to change the 
guidelines. They are three levels of recommendation 
importance distinguished in the presented guidelines: 
 — 1A — strong recommendation, high-quality evi-
dence;
 — 1B — strong recommendation, moderate-quality 
evidence; 
 — 1C — strong recommendation, low- or very low-qual-
ity evidence;
 — 2A — weak recommendation, high-quality evidence;
 — 2B — weak recommendation, moderate-quality 
evidence; 
 — 2C — weak recommendation, low- or very low-qual-
ity evidence.
Guidelines without brackets (with very few publi-
cations of low reliability, including ambiguous expert 
opinions) were considered by experts and scientific 
societies as currently suggested clinical management. 
Recommendations based on current literature could 
differ from current summaries of product characteristics.
2. Venous thromboembolism (VTE)
The term “venous thromboembolism” includes the 
cases of DVT and PE; however, the former is a primary 
event and the latter is a secondary result. In approxi-
mately half of patients DVT is asymptomatic. In half of 
patients with DVT of the proximal part, asymptomatic 
(clinically silent) PE could be diagnosed. In many pa-
tients PE leading to death is the very first and only sign 
of VTE [34].
2.1. Complications of VTE 
Acute complications of DVT could cause PE, and in 
patients with ventricular septal defect (VSD) or atrial 
septal defect (ASD) even stroke or peripheral embolism.
Post-thrombotic syndrome (PTS) is a chronic com-
plication of DVT, occurring in 20–50% of patients with 
DVT, often leading to chronic venous insufficiency 
(CVI), which manifests as pain of extremities, skin dis-
coloration, and varicosities, and in the most advanced 
cases with hard-to-heal ulcerations.
The outcome of acute PE can be fatal in 2–8% of 
patients. In 2–4% of patients, high risk or recurrent 
PE could lead to development of chronic thromboem-
bolic pulmonary hypertension, which manifests as right 
ventricular heart failure, dyspnoea, oedema of lower 
extremities, and impaired exercise tolerance. This com-
plication is associated with poor prognosis. 
Chronic complications of VTE are an important 
clinical problem due to their incidence and high cost of 
diagnostic and therapeutic procedures. Additionally, in 
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advanced stages they cause long-term inability to work 
and decreased quality of life [34].
2.2. Diagnosis of VTE
The patient’s physical examination should consider 
risk factors (subunit 3.1), symptoms related to location 
of disease (subunit 3.4), and in the case of suspicious of 
PE — previous or recent episodes of DVT.
Active malignant disease classifies patients to 
a group with at least moderate risk of VTE. Thus, cancer 
patients with clinical symptoms of VTE warrant immedi-
ate diagnostic tests, e.g. ultrasound (US) examination 
of deep veins in case of DVT symptoms and computed 
tomography angiography (angio-CT) of pulmonary ar-
teries and US of deep veins in case of PE suspicious [34].
2.3.	Prevention	of	VTE
Occurrence of VTE in cancer patient worsens the 
prognosis and decreases health-related quality of life [35]. 
Appropriate antithrombotic prevention used in cancer 
patients with high risk of VTE in non-surgical departments 
and in some outpatient patients could decrease the inci-
dence of VTE and thereby mortality due to PE [6, 36–38]. 
2.4. Treatment of cancer patients with VTE
Antithrombotic treatment of cancer patients with 
VTE is divided into three phases (Figure 1):
 — initial treatment — 7–10 days;
 — long-term treatment — up to 3–6 months; 
 — chronic treatment — after 3–6 months [23]. 
Pulmonary embolism is divided into three categories: 
low, moderate and high risk or (much simplified) into 
categories that warrant (high risk) or do not warrant 
thrombolytic treatment.
2.5.	Antithrombotic	drugs	in	prevention	 
and treatment of patients with VTE 
2.5.1. Low-molecular-weight heparin (LMWH) 
administered subcutaneously (s.c.)
Dosing of LMWH in prevention of VTE:
 — dalteparin 5000 IU every 24 hours;
 — enoxaparin 40 mg every 24 hours;
 — nadroparin 3800 IU every 24 hours, in patients of 
body weight over 70 kg 5700 IU every 24 hours [39].
Dosing of LMWH during initial treatment of VTE 
(in alphabetical order): 
 — dalteparin (100 IU/kg every 12 hours or 200 IU/kg 
every 24 hours) — during initial treatment dosing 
every 12 hours is preferred;
 — enoxaparin (1 mg/kg every 12 hours or forte form 
1.5 mg/kg every 24 hours);
 — nadroparin (86 IU/kg = 0.1 ml/kg b.w. every 12 hours 
or 171 IU/kg b.w. = 0.1 ml/kg every 24 hours) [39].
2.5.2. Unfractionated heparin (UFH)
Dosing of UFH in prevention of VTE:
 — 5000 IU every 8 hours IV or s.c.
Dosing of UFH during initial treatment of VTE:
 — initial dose of UFH (bolus) could be adminis-
tered IV and should be adjusted to body weight 
and amount to 80 IU/kg b.w. (although not lower 
than 5000 IU), then — IV with APTT monitoring 
(during continuous infusion APTT should be pro-
longed 1.5–2.5-fold as compare to control, which 
reflects a drug serum concentration of 0.3–0.6 IU 
of anti-Xa activity);
 — the infusion rate is based on body weight and 
amounts to 18 IU UFH/kg b.w./hour, provided that 
it is not lower than 1250 IU/hour; 
 — UFH could be also administered s.c.; in those 
cases UFH is initially administered IV in the dose 
of 5000 IU in bolus and then s.c. 17500 IU every 
12 hours with APTT monitoring;
 — during establishing of UFH dose Reschke normo-
grams could be helpful [40];
 — although the risk of heparin-induced thrombocyto-
paenia (HITT) during treatment with UFH is low, 
from the 4th to 14th day of UFH therapy or to UFH 
therapy termination, platelets count should be as-
sessed every 2–3 days. Patients previously treated 
with heparin could warrant earlier assessment of 
platelet count as well as more frequent monitoring of 
this parameter considering the possibility of earlier 
occurred HITT;
 — UFH should be administered for 5–7 days, and in jus-
tified cases therapy should be prolonged to 10 days. 
2.5.3. Fondaparinux 
Dosing of fondaparinux in prevention of VTE:
 — 2.5 mg every 24 hours s.c.
Dosing of fondaparinux in the treatment of VTE:
 — every 24 hours s.c. in doses:
•	 in	patients	with	body	weight	below	50	kg	—	5	mg;
•	 in	patients	with body weight between 50–100 kg 
— 7.5 mg;
•	 in	patients	with	body	weight	over	100	kg	—	10	mg.
Figure 1. Phases of antithrombotic treatment of cancer patients 
with venous thromboembolism
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2.5.4. Vitamin K antagonists (VKA) (acenocoumarol 
and warfarin) 
VKA are used orally with monitoring of pro-
thrombin time (PT) converted into the INR value 
(INR value should be in the range between 2.0–3.0; 
in patients with higher bleeding risk INR should be 
about 2.0).
In patients taking VKA in stable dose (after its 
establishment) it is suggested to measure INR not 
less frequently than every four weeks. In patients tak-
ing VKA in stable dose with INR values significantly 
varying, more frequent INR assessment is suggested 
— every 1–2 weeks [2C]. Patients should receive dietary 
counselling about vitamin K levels in food products 
and possible drug-drug interactions, especially with 
over-the-counter (OTC) drugs. For stability of vitamin 
K treatment a balanced diet is needed with similar daily 
dose of vitamin K.
2.5.5. Direct oral anticoagulants (DOAC)
Currently they are not recommended in cancer 
patients with VTE. LMWH is a drug of choice in can-
cer patients using DOAC for other indications, e.g. 
cardiological, especially atrial fibrillation, and those 
who experienced VTE, because such incidence suggests 
failure of anticoagulation. LMWHs are not recom-
mended in chronic stroke prevention in patients with 
atrial fibrillation.
 — Oral direct thrombin inhibitors:
•	 dabigatran.
 — Oral direct inhibitors of factor Xa:
•	 rivaroxaban,	apixaban,	edoxaban.
2.6. Contradictions to pharmacological 
antithrombotic treatment
Contraindications to antithrombotic treatment 
should be considered in each case of decision making 
about the use of those drugs in cancer patients.
Absolute contraindications include the following:
 — clinically important haemorrhagic diathesis;
 — active bleeding;
 — dissecting aortic aneurysm;
 — haemorrhagic stroke (two weeks to three months 
from incidence, depending on thromboembolic risk); 
 — hypertensive crisis;
 — infective endocarditis;
 — HITT — only related to UFH and LMWH.
Relative contraindications include the following:
 — active peptic ulcer disease;
 — primary or metastatic neoplasm of central nerv-
ous system;
 — severe hepatic insufficiency with tendency to bleed. 
IMPROVE scale facilitates assessment of bleeding 
risk (Table 1) [41].
aAccelerated scheme is preferred. Compare to standard dosing, administration 
of thrombolytic drugs according to the accelerated scheme is associated with 
faster dissolution of the thrombus and decreased risk of bleeding.
Table 1. Point scale for bleeding risk assessment in 
hospitalised, acutely ill patients with no need for surgical 
intervention, with own modification (so called IMPROVE 
scale) [41] 
Bleeding risk factor Number of 
points
eGFR ≥ 60 ml/min/m2 1
Male gender 1
Age 40–84 years 1
Malignant disease 2
Rheumatic disease 2
Central vein catheter 2
Hospitalisation in intensive care unit or 
cardiological intensive care unit
2.5
eGFR < 30 ml/min/m2 2.5
Hepatic insufficiency (INR > 1.5) 2.5
Age ≥ 85 years 3.5
Platelets count < 50 G/l 4
Bleeding during last three months before 
hospitalisation
4
Active gastric and duodenal peptic ulcer 
disease
4.5
High bleeding risk > 7
eGFR — estimated glomerular filtration rate; INR — international normalised 
ratio
2.7.	Non-pharmacological	methods	for	
antithrombotic prevention
During use of pharmacological antithrombotic pre-
vention in patients immobilised due to acute disease it is 
recommended to concomitantly use mechanical prevention 
methods with graduated compression stockings (PESU) or 
intermittent pneumatic pressure devices (PUP). Mechani-
cal prevention is also recommended in the case of contrain-
dication to pharmacological antithrombotic prevention.
2.8. Thrombolytic drugs 
Dosing in systemic administration during treatment 
of patients with PE:
— alteplase (rt-PA):
•	 standard	scheme:	100	mg	IV	during	two	hours;
•	accelerated	scheme	(rarely	used):	0.6	mg/kg	b.w.	
(max. 50 mg) during 15 minutes;
— streptokinase (SK):
•	accelerated	scheme	(preferreda): 1.5 mln IU IV 
during 2 hours;
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 — stroke;
 — paresis of lower extremities, long-term immobilisa-
tion;
 — previous VTE;
 — congenital acquired thrombophilia;
 — sepsis; 
 — bedridden patient treated conservatively (e.g. due 
to severe pneumonia);
 — heart failure of III and IV NYHA class;
 — respiratory failure;
 — autoimmune diseases;
 — nephrotic syndrome;
 — paroxysmal nocturnal haemoglobinuria;
 — pressure on vein (e.g. mass, haematoma, arterial mal-
formation);
 — pregnancy and childbed;
 — long-term immobility due to advanced cancer, travel-
ling (e.g. flight);
 — varicose veins of lower extremities;
 — acute infection.
3.2.	Cancer-related	risk	factors	of	VTE
 — localization of the cancer (mainly pancreatic, gastric, 
lung, kidney, ovary cancer, and brain malignant 
tumours); 
 — histopathology of cancer (VTE is most common 
in adenocarcinomas);
 — cancer clinical stage;
 — increased D-dimer levels exceeding two-fold cut-off 
value could suggest increased risk of VTE [42]. It 
should be also underlined that isolated (e.g. with 
no relation with the clinical presentation) increased 
D-dimer level is never an indication to initiation of 
antithrombotic drug administration; 
 — the highest incidence of VTE is observed within the 
first 3–6 months after diagnosis of cancer. 
3.3.	Treatment-related	risk	factors	of	VTE
 — previous surgical operations, including anaesthesia;
 — chemotherapy or hormone therapy;
 — antiangiogenic treatment;
 — radiotherapy;
 — transfusion of red cell concentrates;
 — erythropoiesis stimulating agents (ESA); 
 — corticosteroids;
 — central catheters [3, 4, 8].
3.3.1. Chemotherapy
Chemotherapy increases the risk through several 
mechanisms, including impairment and/or activation of 
vascular endothelial cells, decreased level of natural co-
agulation inhibitors, and platelets activation [3, 4, 43]. 
The results of prospective RCTs showed a significant 
•	standard	scheme:	250,000	IU	IV	during	30	min-
utes, then 100,000 IU/hour during 12–24 hours;
— urokinase: 
•	accelerated	scheme:	3	mln	IU	IV	during	two	hours.
•	standard	scheme:	4400	IU/kg	IV	during	10	min-
utes, then 4400 IU/hour during 12–24 hours.
Dosing during administration to implantable port 
system: 
— rt-PA IV in the dose of 0.9 mg/kg b.w. (max. 90 mg):
•	 10%	of	calculated	dose	in	bolus	during	2	minutes;
•	 remaining	90%	of	dose	IV	during	60	minutes.
2.9.	Contradictions	to	thrombolytic	drugs	
according	to	2014	European	Society	of	Cardiology	
guidelines	[29]
Absolute contraindications include the following:
 — active bleeding to internal organs;
 — dissecting aortic aneurysm;
 — haemorrhagic stroke; 
 — cerebrovascular diseases (aneurysms, arteriovenous 
fistula, vascular malformations);
 — tumours of central nervous system;
 — ischaemic stroke within last six months;
 — head trauma or multiple organ injury or surgery 
within last three weeks. 
Relative contraindications include the following:
 — episode of transient ischaemic attack within last 
six months;
 — bleeding in the gastrointestinal or urinary tract;
 — resuscitation procedures leading to organs injury;
 — hypertension with values exceeding 200/120 mm Hg;
 — severe hepatic insufficiency;
 — bacterial endocarditis;
 — pregnancy or first week after giving birth;
 — active peptic ulcer disease;
 — status after biopsy of an organ not susceptible 
to pressure.
Detailed part
3. Risk factors, symptoms, forms, and 
diagnosis of VTE
3.1.	Patient-related	risk	factors	of	VTE
The same as in population of non-cancer patients [23, 42]:
 — age > 40 years (increased risk with age);
 — obesity (BMI > 30 kg/m2);
 — positive family history of VTE;
 — injuries (especially multiple organs or fracture of 
the bones of pelvis, proximal part of the femur, and 
other long bones of lower extremities);
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decrease in VTE incidence in outpatients undergoing 
chemotherapy, receiving pharmacological antithrom-
botic prevention, as compare to patients without 
prevention [44–47]. Patients with pancreatic and lung 
cancer especially benefit from such prophylaxis [45, 
47–56]. Patients who underwent systemic therapy in 
clinical settings differed significantly from patients re-
cruited to clinical trials, as they have worse performance 
status, more advanced age, and more concomitant dis-
eases, thus they are more likely to develop either VTE 
or bleedings. The type of cancer and its clinical stage, 
modality of systemic therapy and its duration, combina-
tion of systemic therapy with irradiation and supportive 
care, response to anticancer therapy (e.g. tumour lysis 
syndrome), patient’s nutritional status, hepatic and 
renal function, patient’s mobility, and vascular stasis all 
definitely influence the risk of VTE in cancer patients.
3.3.2. Hormone therapy
Monotherapy with tamoxifen is associated with 
a 2–3% risk of VTE, and this risk increases with pa-
tient’s age; breast cancer postmenopausal women are 
three-fold more likely to develop VTE than patients 
before menopause. Aromatase inhibitors are associated 
with VTE less frequently than tamoxifen; however, the 
risk of VTE is significantly higher than in the healthy fe-
male population who did not undergo such therapy [3, 4].
In patients with pancreatic cancer during hormone 
therapy the risk of DVT and PE significantly increases 
as compared to such patients without hormone therapy. 
The risk of VTE is extremely high during therapy with 
GnRH agonists and oral antiandrogens, and longer 
hormone therapy duration in men is associated with 
more frequent VTE [57, 58].
3.3.3. Anti-angiogenic treatment
The prevalence of VTE is estimated to amount to 
several to several dozen per cent, depending on which 
anti-angiogenic drug is used (e.g. bevacizumab, thalido-
mide, lenalidomide, pomalidomide, gefitinib) [58–65]. 
The results of meta-analysis indicate the increased 
relative risk of VTE after treatment with bevacizumab 
(monoclonal antibody against vascular endothelial 
growth factor [VEGF]) [59]. The general prevalence 
of VTE in this group of patients is 10.9% [60]. How-
ever, in patients with multiple myeloma the highest 
prevalence of VTE (34%) was noted during treatment 
with thalidomide in combination with doxorubicin, as 
well as in patients receiving lenalidomide together with 
high doses of dexamethasone due to recurrent disease 
[61]. It should be underlined that procoagulant effect of 
anti-angiogenic treatment increases through combina-
tion with cytotoxic drugs or corticosteroids.
Venous thromboembolism risk factors in myeloma 
patients include:
 — patient-related factors: older age, obesity, sedentary 
lifestyle, immobilisation, past episode of VTE, and 
genetic predisposition to VTE;
 — disease-related factors: renal insufficiency, abnor-
malities in chromosome 11, increased CRP level, 
and short-chain disease;
 — treatment-related factors: immunomodulatory drugs 
(thalidomide, lenalidomide, pomalidomide) used 
alone or in combination with cytotoxic drugs [62].
The majority of VTE episodes in patients with multi-
ple myeloma are diagnosed during the initial treatment 
period [62].
3.3.4. Radiotherapy
Radiotherapy increases the risk of thrombosis 
through release of procoagulants and cytokines 
from cancer cells and directly through impairment 
of vascular vessels, thereby causing activation of vas-
cular endothelial cells, leucocytes, and platelets; this 
increases also aggregation potential of these latter 
[63]. Additionally, radiotherapy leads to loss of natu-
ral vascular resistance against thrombus formation. 
Moreover, acute radiation reaction after radiotherapy 
favours infections, which additionally potentiate pro-
coagulant status. 
There is lack of large RTCs, documenting the 
incidence of VTE in patients who have undergone 
radiotherapy on different body areas due to a wide 
range of cancers. However, it was noted that in patients 
with Hodgkin’s lymphoma irradiated on the area of 
mediastinal lymph nodes and in patients with left breast 
cancer during adjuvant radiotherapy the risk of cardio-
vascular complications is 2–7-fold higher as compare to 
patients without irradiation of that area. The risk of the 
mentioned complications increases when the radiation 
dose administered on anterior heart surface exceeds 
35–40 Gy [63]. However, it should also be underlined 
that contemporary treatment of cancer patients is 
based on combination therapy, and a large proportion 
of those patients receive radiotherapy in combination 
with chemotherapy or targeted therapies. For example, 
radiotherapy in patients with endometrial or cervical 
cancer is associated with approx. 5–7% risk of VTE, 
whilst radiotherapy in combination with cisplatin in-
creases the risk of VTE in this group of patients up to 
8.5–16.7% [63]. Venous thromboembolism was also 
reported after combination therapy (radiotherapy, 
chemotherapy, and/or targeted therapy) in patients 
with gastric, oesophageal, head-and-neck cancers as 
well as malignant brain tumours. Radiotherapy on the 
chest area in patients with indwelling central venous 
catheter is an independent risk factor of VTE occur-
ring in upper extremities (OR 7.01; 95% CI 1.42–34.66) 
[literature review in 63].
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The patients underwent palliative radiotherapy quite 
frequently are characterised by limited mobility or even 
immobilisation, which could be the cause of approx. 
15% of VTE cases. Use of high fractionated doses in 
patients during palliative radiotherapy could lead to 
tumour lysis syndrome and releasing procoagulants 
and cytokines from cancer cells, increasing risk of VTE. 
Moreover, those patients often enough receive support-
ive care, which additionally increases the risk of VTE 
(e.g. cancer-related cachexia treatment — megestrol). 
In patients undergoing palliative radiotherapy the 
bleeding risk could be even higher considering the large 
tumour volume, often infiltrating vascular walls of dif-
ferent calibre blood vessels, as well as the possibility of 
hypoproteinaemia and hepatic and renal dysfunctions 
in advanced cancer stages.
3.4.	Symptoms	and	forms	of	VTE
3.4.1. Lower extremities VTE
The symptoms of lower extremities VTE could in-
clude: increased extremity girth, oedema, erythema, or 
calf tenderness lower extremity.
3.4.2. Upper extremities VTE
Deep venous thrombosis in upper extremities could 
cause different symptoms, including oedema, erythema, 
and excessive warmth as well as pain and paraesthesia 
of upper extremities, pain in shoulder, axilla, lower 
jaw, head and neck, and visible enlargement of veins in 
collateral circulation in the area of the shoulder joint 
and chest. Symptoms of superior vena cava syndrome 
(SVCS) could be also detected. Difficulties in obtain-
ing blood samples from central catheter or in IV fluids 
infusion through the catheter suggests thrombosis of 
the end of the catheter. 
3.4.3. Pulmonary embolism (PE)
Symptoms of PE are very different and depend on 
embolism extent and the patient’s general condition. 
The most common symptoms of PE include: tachycar-
dia (80% of patients), tachypnoea, dyspnoea (50% of 
patients), pleural pain (40% of patients), cough (25% 
of patients), and more rarely (< 10% of patients) the 
following: increased body temperature, haemoptysis, 
collapse, or fainting. 80% of patients with PE also have 
the symptoms of DVT. 
3.4.4. Migratory thrombophlebitis 
(Trousseau syndrome)
It affects only superficial veins, most frequently of 
atypical location (e.g. veins of upper extremities, chest), 
and is characterised by spontaneous regressions and 
recurrences. This entity is not included into the term 
of VTE, but this is a rare but characteristic syndrome 
of coagulation disorders in cancer patients. Resistance 
against antithrombotic treatment is commonly observed.
3.4.5. Marantic endocarditis
Physical examination reveals new-onset heart mur-
murs and symptoms of disseminated embolism in cer-
ebral, coronary, splenic, renal and limbs arteries. Very 
often the first symptom of this disease is ischemic stroke 
with no new heart murmurs.
3.4.6. Hepatic vein thrombosis  
(Budd-Chiari syndrome)
The symptoms of this form of VTE include: abdo-
men discomfort, presence of ascites, hepatomegaly, and 
abdominal pain. 
3.4.7. Thrombosis in the portal vein, splenic vein, 
mesenteric vein, and the renal veins
These are quite frequent forms of VTE in patients 
with non-proliferative cancers and in patients with 
primary hepatic, pancreatic, kidney, and suprarenal 
cancers. Clinical symptoms include: abdominal pain, 
splenomegaly, oesophageal varices, and ascites.
3.4.8. Incidental VTE
An asymptomatic course of DVT and/or PE is 
relatively common in cancer patients [63]. Thrombus 
in pulmonary artery is accidentally detected in approx. 
3% of patients, in which angio-CT is performed due to 
indications other than suspicion of PE. Cancer patients 
are considered to be especially exposed to incidental 
VTE localised in the abdomen [64–68]. It affects 2–5% 
of patients in which abdomen CT is performed. 
Symptoms of VDT and PE are not characteristic, and 
in many cases they raise no concerns among patients as well 
as clinicians. Deep venous thrombosis symptoms could also 
be attributable to cancer but not to new pathology [68, 69]. 
It is worth pointing out that VTE is observed in 
cancer patients regardless of whether the DVT and/or 
PE episode was symptomatic or asymptomatic [70]. 
3.5.	Diagnosis	
Diagnosis of VTE in cancer patients differs from the 
diagnostic rules accepted for remaining patients with 
VTE [71–75]. In the majority of cancer patients D-dimer 
levels could be increased without simultaneous VTE. 
However, a D-dimer level below the cut-off value (“nega-
tive D-dimer”) does not exclude VTE in cancer patients. 
VTE diagnosis should include US examination of 
deep veins, which ensures sensitivity and specificity of 
about 93–100% related to proximal VTE and over 70% in 
the case of the calf VTE using following techniques [34]:
 — compression test in B presentation;
 — pulse Doppler method;
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 — colour Doppler sonography;
 — duplex Doppler technique.   
Palaeography and angio-CT of venous vessels or 
magnetic resonance angiography (angio-MR) (mainly 
in suspicions of DVT of iliac veins and thrombosis of 
superior and inferior vena cava — in borderline cases or 
proximal DVT of lower extremities) are less frequently 
performed [23].
Diagnosis of PE in cancer patients is based on 
angio-CT of pulmonary arteries, or less frequently on 
ventilation-perfusion scintigraphy [73].
Guidelines:
1. In the case of occurrence of PE and/or DVT clinical 
symptoms, diagnostic tests should be immediately 
performed — US of deep veins in the case of DVT 
symptoms and angio-CT of pulmonary arteries in 
suspicion of PE. 
2. In cancer patients with clinical symptoms of DVT 
and/or PE antithrombotic treatment should be 
immediately initiated while waiting for results of 
diagnostic imaging tests [2C].
3.6.	Searching	for	cancer	in	patients	with	VTE	 
or PE — occult malignancy
The symptoms of VTE could precede the diagnosis 
of malignant disease [76, 77]. In up to 10% of patients 
cancer is diagnosed within several to several dozen 
months (most commonly during the first six months) 
from idiopathic thrombosis episode — so-called occult 
malignancy. The most frequent are prostate and colon 
cancers and more rarely lung, pancreatic, gastric, and 
bladder cancers [78]. Recently identified risk factors of 
occult malignancy in patients after first VTE episode 
include: age > 60 years, current smoking, and previous 
VTE episode due to transient factor [79].
The SOMIT study indicated that intensive screening 
diagnosis towards cancer in patients with VTE episode 
increases the rate of malignant disease diagnosed in 
early stages, but is not associated with prolonged OS 
as compare to patients who have undergone routine 
assessment towards cancer disease [80]. 
Published in 2015, a Canadian randomised study did 
not reveal significant differences in the rate of cancer 
diagnosis in patients with idiopathic VTE, who had un-
dergone standard diagnostic evaluation towards cancers 
with consideration of gender and age, medical history, 
morphology and biochemical blood tests, chest X-ray, in 
women: mammography and cytology exam, and in men: 
PSA level and prostate palpation, as compared to individu-
als in which standard evaluation was extended by abdomi-
nal and pelvic CT, virtual colonoscopy, and gastroscopy. In 
the first group, cancers were diagnosed in 3.2% of patients 
compared to 4.5% in the second group [81].
The incidence of cancers is higher in patients with 
significantly increased D-dimer levels during the initial 
disease phase [82–85], and in patients with bilateral DVT 
[84] and with early relapse of VTE [86].
Guidelines: 
1. Routine extended diagnostic assessment towards 
malignant disease in every patient with an episode 
of idiopathic VTE is not recommended. This pro-
cedure could be indicated in elderly patients, with 
significantly increased D-dimer levels during initial 
disease phase, and in patients with bilateral DVT 
and with early relapse of VTE [2C].
2. Detailed physical examination and basic diagnostic 
tests, including chest X-ray, faecal occult blood test, 
urological examination in men, and gynaecological 
examination in women should be performed in every 
patient with an episode of idiopathic VTE [2C].
3. In patients with VTE and with justified clinical 
suspicion of malignant disease the diagnosis should 
be extended towards cancer (CT, endoscopic evalu-
ations, abdominal US, cancer-related markers) [2B].
4. Prevention of VTE in patients with 
cancers treated non-surgically
4.1. Prevention of VTE in hospitalised, medically ill 
cancer patients
Three large RCTs, including cancer patients 
(5–15%), indicated that antithrombotic prevention in 
acutely ill patients, immobilised in hospital settings, sig-
nificantly decreased the incidence of VTE as compared 
to placebo, with low bleeding rates after use of LMWHs 
or fondaparinux [87–89]. Some cancer patients are 
hospitalised without any other acute diseases. In those 
cases, the Padua Prediction Score could be helpful to 
estimate the risk of VTE (Table 2) [90].
There is a lack of unambiguous data from clinical 
studies regarding the use of routine antithrombotic pre-
vention in patients hospitalised for cancer diagnosis or to 
administer short-term intravenous infusion of anticancer 
drugs. In those cases the decision of antithrombotic 
prevention initiation should be made individually.
Guidelines:
1. Antithrombotic prevention with LMWHs, UFH 
(subunit 2.5), or fondaparinux in hospitalised, medi-
cally ill cancer patients is recommended [1A].
2. In hospitalised, medically ill cancer patients with pre-
vious VTE episodes, or in those immobilised or with 
venous blood flow from a lower body part blocked by 
a growing tumour, antithrombotic prevention with 
LMWHs, UFH, or fondaparinux (subunit 2.5) is 
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Table 2. Assessment of risk factors of venous thromboembolism (VTE) in hospitalised patients — Padua Prediction Score [90]
Risk factors Score
Active malignant disease (patients with metastases to regional lymph nodes or with distant metastases, undergoing 
chemotherapy or radiotherapy during the last 6 months) 
3
Past VTE (except thrombosis of superficial veins) 3
Immobility (assumed need for staying in bed [with possibility of using bathroom/toilet] due to patient’s disability or 
physician order for ≥ 3 days)
3
Diagnosed thrombophilia (antithrombin, protein C or S deficiency, mutation of factor V Leiden, mutation G20210A  
in prothrombin gene or antiphospholipid syndrome)
3
Recently past (≤ 1 month) injury or surgery 2
Age ≥ 70 years 1
Heart or respiratory failure 1
Recent myocardial infarction or ischaemic stroke 1
Acute infection or rheumatic disease 1
Obesity (BMI ≥ 30 kg/m2) 1
Hormone therapy 1
Total result ≥ 4 points indicates high risk of VTE 
Total result < 4 points indicates low risk of VTE
VTE — venous thromboembolism; BMI — body mass index
Table 3. Khorana Risk Score (with ASCO modification) of 
venous thromboembolism risk in outpatients undergoing 
chemotherapy [8, 91]
Risk factors Score
Target organ and histological type
Very high risk
	 •	gastric adenocarcinoma
	 •	pancreatic adenocarcinoma
	 •	malignant brain tumours
2
High risk
	 •	lung cancer
	 •	lymphomas
	 •	gynaecological cancers
	 •	bladder cancer
	 •	testicular cancer
	 •	kidney cancer
1
Haematological risk factors
	 •	platelets count before chemotherapy ≥ 350 G/l
	 •	haemoglobin level < 10 g/dl or ESA using
	 •	leucocyte count before chemotherapy > 11 G/L
1
1
1
Patient-related factors
	 •	BMI ≥ 35 kg/m2 1
ESA — erythropoiesis stimulating agents; BMI — body mass index
recommended, provided there are no contraindications 
to pharmacological antithrombotic prevention or high 
risk of haemorrhagic complications (subunit 2.6) [1C].
3. In hospitalised cancer patients with increased risk of 
VTE, use of mechanical antithrombotic prevention 
should be considered (PUP and PESU — subunit 
2.7) [2C].
4. Routine antithrombotic prevention is not recom-
mended in cancer patients hospitalised for diagnostic 
evaluation or for administration of short-term intra-
venous infusion of cytotoxic drugs [2C].
5. Pharmacological antithrombotic prevention is not 
recommended in cancer patients with current bleed-
ing or with high risk of bleeding (subunit 2.6). In 
those cases, mechanical antithrombotic prevention 
(PUP and PESU — subunit 2.7) is recommended.
6. It is recommended not to use acetylsalicylic acid 
(ASA) as a single method of antithrombotic preven-
tion during hospitalisation [2C].
4.2. Prevention of VTE in outpatients undergoing 
non-surgical anticancer treatment
Prevention of VTE should be introduced only in 
patients with increased risk of that disorder. For this 
reason, the scale of VTE risk assessment in cancer 
patients receiving chemotherapy in outpatient settings 
(the so-called Khorana Risk Score) was developed and 
validated (in the PROTECHT and SAVE-ONCO stud-
ies) (Table 3) [91–93]. According to this score, patients 
are divided into three groups, e.g. with low (0 points), 
moderate (1–2 points), and high (more than 3 points) 
risk of VTE induced by chemotherapy (Table 2). VTE 
risk in particular groups accounts for 0.3%, 2%, and 
6.7%, respectively. This predictive model allows identi-
fication of the patients with high risk of VTE [2B]. The 
Khorana Risk Score (Table 3) does not include poor 
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general patient state and some types of cancers con-
nected to high risk of VTE, for example brain tumours. 
The Khorana Risk Score of VTE risk in cancer 
patients undergoing chemotherapy was modified by Ay 
et al. [94]. They added serum P-selectin and D-dimer 
levels to five parameters covered by the original model. 
The probability of symptomatic or fatal VTE is then 
35% in patients with ≥ 5 risk factors, 10.3% with 3 risk 
factors, and 1.0% with no risk factors. The limitation 
of the modified score is that P-selectin is not routinely 
assessed in clinical practice and there are no tests reg-
istered for clinical use.
To date there is no strong evidence justifying rou-
tine antithrombotic prevention in patients undergoing 
radical radiotherapy or radiochemotherapy or palliative 
radiotherapy. 
Guidelines:
1. Routine antithrombotic prevention in cancer patients 
undergoing chemotherapy in outpatient settings is 
not recommended [2C].
2. Antithrombotic prevention could be considered in 
patients undergoing chemotherapy in outpatient 
settings with high risk of VTE, e.g. in patients with 
advanced pancreatic cancer [1B] or non-small cell 
lung cancer (NSCLC), provided that they have low 
risk of bleeding and no contraindications to antico-
agulants [2B].
3. Every patient with multiple myeloma should be 
assessed for VTE risk (subunit 3.1) and receive ap-
propriate antithrombotic prevention [1A].
4. Patients with multiple myeloma are recommended 
to receive the following VTE prevention [62]:
a. ≤ 1 VTE risk factor: ASA in the dose of 100 mg/d 
[1B];
b. ≥ 2 VTE risk factors: LMWHs in prophylactic 
dose or VKA with target INR value between 
2.0–3.0 [1B];
c. LMWH should be administered for at least four 
months and then could be replaced by ASA [2C].
5. In the remaining patients undergoing chemotherapy 
in outpatient settings the decision of antithrombotic 
prevention initiation should be made individually, 
based on analysis of VTE risk (subunit 3.1) and 
individual assessment of benefits and possible com-
plications of such prevention.
6. It is recommended that ASA is not used as the single 
method of antithrombotic prevention [2C].
7. In cancer patients undergoing chemotherapy in 
outpatient settings with increased risk of VTE use of 
PUP and PESU should be considered (subunit 2.7).
8. Routine antithrombotic prevention in patients un-
dergoing radical radiotherapy, radiochemotherapy, 
or palliative radiotherapy is not recommended.
9. In patients during radical radiotherapy, radiochemo-
therapy, or palliative radiotherapy the decision of 
antithrombotic prevention initiation should be made 
individually with consideration of VTE risk factors, 
associated with general patient’s state, concomitant 
diseases, cancer type and stage, and combination of 
radiotherapy with systemic treatment.
4.3.	Antithrombotic	prevention	in	patients	with	
indwelling central venous catheter
Clinically overt subclavian artery thrombosis occurs 
in approx. 5% of patients; however, incidental for of that 
disorder is diagnosed in up to 14–18% of patients with 
indwelling central venous catheters [95]. There is no 
evidence of LMWH or VKA efficacy in VTE prevention 
in patients with indwelling central venous catheters [96].
Guidelines:
1. Routine antithrombotic prevention in cancer patients 
with indwelling central venous catheters is not recom-
mended [2C].
2. Catheters should be inserted on right body side; how-
ever, the catheter’s end should be placed close to the 
superior vena cava-right atrium junction in order to 
decrease the risk of thromboembolic complications 
[2C].
3. Antithrombotic prevention in patients with high VTE 
risk should be individualised [2C].
4.4. Prevention of VTE in patients with concomitant 
thrombocytopaenia
Guidelines of antithrombotic prevention use in pa-
tients with thrombocytopaenia are based on data from 
observational studies, conducted in relatively small 
groups of patients treated in single centres [97–103]. 
In this group of patients mechanical VTE prevention 
methods could be used, except for pharmacological 
antithrombotic prevention. 
Guidelines:
1. In acutely ill patients with active cancer, hospitalised 
due to non-surgical disease, pharmacological VTE 
prevention is recommended in standard doses, 
provided that platelet count is ≥ 50 G/l and there 
are no symptoms of haemorrhagic diathesis and no 
additional haemostasis disorders [2C].
2. When the platelet count is 25–50 G/l and there are 
no symptoms of haemorrhagic diathesis the decision 
of using anticoagulants in standard doses or their de-
crease or abandonment of antithrombotic prevention 
should be based on analysis of potential benefits and 
risk resulted from the therapy [2C].
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3. In patients with platelet count < 25 G/l it is suggested 
not to use antithrombotic prevention, and in this 
case mechanical antithrombotic prevention methods 
(PUP and PESU — subunit 2.7) could be used [2C].
4. When thrombocytopaenia is accompanied by ac-
tive haemorrhagic diathesis and/or concomitant 
haemostasis disorders it is suggested not to use 
pharmacological antithrombotic prevention. In this 
case mechanical VTE prevention methods are rec-
ommended (PUP and PESU — subunit 2.7).
5. The above recommendations relate also to cancer 
patients with concomitant thrombocytopaenia, 
who needed antithrombotic prevention for reasons 
other than hospitalisation due to acute non-surgical 
disease, e.g. outpatients.
4.5.	Antithrombotic	prevention	in	patients	with	
concomitant	renal	insufficiency	
During chronic renal disease with declined eGFR 
not only pharmacokinetics of anticoagulant drugs ex-
creted by the kidney (LMWHs, fondaparinux, DOAC), 
but also plasma protein binding and distribution 
volume are changed. The risk of bleeding complica-
tions in patients with impaired renal function during 
use of anticoagulants is increased due to decreased 
clearance of the drugs and their prolonged activity. 
Other factors increasing the risk of bleedings include: 
older age, obesity, and concomitant use of antiplatelet 
drugs. There is a lack of large, prospective RCTs as-
sessing the efficacy and safety of anticoagulant drugs 
in this group of patients. Thus, the potential benefits 
and bleeding risk during use of anticoagulants in pa-
tients with impaired renal functions should always be 
assessed individually.
Guidelines [23, 104, 105]: 
1. In patients  with impaired renal  function 
(eGFR < 30 ml/min) UFH in the dose of 5000 IU 
s.c. every eight hours is preferred because elimination 
half-life of LMWHs and fondaparinux is prolonged 
in renal insufficiency, and those drugs could be ac-
cumulated in plasma [2C]. 
a. When long-term administration of LMWHs is 
indicated in patients with impaired renal func-
tion the measurement of anti-Xa activity during 
dose establishment in serum from blood sample 
obtained four hours after LMWH injection could 
be helpful to decrease bleeding risk. Target value 
of anti-Xa should not exceed 0.5 IU/ml;
b. Administration of LMWH in doses reduced by 
half is an alternative.
2. In patients with high risk of bleeding, who need 
antithrombotic prevention, mechanical preventive 
methods (PUP and/or PESU) are recommended. 
4.6.	Antithrombotic	prevention	in	terminally	ill	
cancer patients treated in hospices
Patients in advanced cancer stage treated in hospices 
are classified into the group of high VTE/PE risk, among 
others due to older age, advanced loco-regional disease 
(vascular stasis caused by external pressure of large tu-
mour mass leads to blood flow disturbance and favours 
VTE), or massive distant metastases as well as reduced 
patient mobility [106]. Clinically overt PE develops in 
approx. 10% of hospice patients [106]. Additionally, it is 
estimated that half of stationary hospice patients report 
clinically asymptomatic DVT [107, 108]. Those patients 
receive different drugs, which could additionally increase 
the risk of VTE, e.g. megestrol, commonly used in cancer 
patients with cachexia, associated with 30% risk of com-
plications, mainly DVT of lower extremities. The main 
benefit of antithrombotic prevention in patients treated 
in hospices, where the best possible quality of life is 
a priority but not obstinate life prolongation, could be re-
ducing the risk of VTE symptoms occurrence, including 
pain, oedema, or dyspnoea [106]. However, there is a lack 
of clinical studies conducted in the patient groups with 
appropriate sample sizes, which could unambiguously 
assess the influence of antithrombotic prevention on 
VTE symptoms or survival of hospice the patients [109].
Antithrombotic prevention in cancer patients treated 
in hospices is a challenge for many reasons: unknown 
influence of quality of life, unclear risk of VTE after 
cessation of antithrombotic prevention, bleeding risk, 
additionally increased in malnourished patients and 
in patients with reduced eGFR, interactions of many 
drugs with VKA, and direct and indirect costs of that 
management [110–113]. 
Guidelines:
1. Routine antithrombotic prevention in all cancer pa-
tients treated in hospices is not recommended [2C].
2. In every patient the decision about antithrombotic 
prevention initiation should be made individually, 
considering VTE risk, co-morbidities, and bleeding 
risk [2C].
4.7.	Prevention	of	VTE	in	pregnant	women	
diagnosed with cancer 
Indications to VTE prevention in pregnant women 
with cancer are the same as in other cancer pa-
tients. Pregnancy increases the risk of VTE occur-
rence; however, other concomitant VTE risk factors 
in pregnant women with cancer justify initiation of 
antithrombotic prevention. Similarly to general an-
tithrombotic prevention in cancer patients, LMWHs 
and UFH are preferred in pregnant women because 
those anticoagulants do not cross the placenta, unlike 
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VKA. VKAs are contraindicated during the first three 
months of pregnancy (due to teratogenic effect), but also 
during second and third trimester they are reluctantly 
used as they increase risk of bleeding in the mother and 
especially in the foetus. DOACs are contraindicated 
during pregnancy [114]. Fondaparinux is not indicated 
during pregnancy, but there are single reports indicating 
its safety and efficacy in VTE prevention in pregnant 
women, e.g. in the case of HITT occurrence.
Elective caesarean section is very rarely compli-
cated by VTE, so routine antithrombotic prevention 
is indicated when there are additional risk factors (e.g. 
cancer) [115, 116].
Guidelines:
1. Indications to VTE prevention in pregnant women 
with cancer are the same as in other cancer patients.
2. LMWHs and UFH are the preferred anticoagulants 
in antithrombotic prevention in pregnant women 
with cancer [2C].
3. Dosing of LMWHs and UFH in pregnant women 
with cancer is the same as in other cancer pa-
tients. However, in the case of additional risk factors, 
e.g. obesity, previous VTE episode, or concomitant 
congenital thrombophilia/antiphospholipid syn-
drome, higher LMWH doses (even therapeutic) 
could be recognised, based on anti-Xa activity when 
necessary [2C].
4. In pregnant women with cancer undergoing caesar-
ean section, pharmacological antithrombotic preven-
tion in standard doses should be used [2C].
5. After occurrence of active haemorrhagic diathesis, 
deep thrombocytopaenia, or other haemostasis dis-
turbances, increasing the bleeding risk in pregnant 
women with cancer and high VTE risk mechanical 
preventive methods (PUP, PESU — subunit 2.7) 
should be considered.
5. Treatment of cancer patients with VTE
The aim of VTE treatment in cancer patients is 
prevention of acute and chronic complications. Cancer 
patients have a 2–5-fold increased risk of VTE recur-
rence and 2–6-fold increased risk of major bleedings 
as compare to the population of patients with VTE 
but without cancer [1–4]. Every time, the bleeding risk 
(subunit 2.6) and potential benefits from antithrombotic 
treatment should be balanced [13, 108]. 
Very often, fast appropriate diagnosis of PE and 
initiation of adequate treatment are of extreme impor-
tance for the further life of patients with PE complicat-
ing the clinical course of cancer [13, 24, 109–111]. The 
majority of PE cases are embolisms that do not require 
thrombolytic treatment. The treatment of patients with 
PE is based on procedures aiming at restoration of pul-
monary vasculature patency, reduction of VTE recur-
rence risk, and maintaining appropriate perfusion and 
oxygen delivery to important organs and systems, despite 
haemodynamic and respiratory disturbances caused by 
PE. There are two main periods of PE treatment: initial 
and long, chronic antithrombotic treatment, continued 
for many months. 
5.1.	Initial	treatment	of	cancer	patients	with	VTE	 
or PE with no need for thrombolytic therapy
The efficacy of LMWHs during initial VTE treat-
ment was comparable to UFH, with lower risk of 
bleeding complications [117–123]. It was observed in 
Cochrane analysis including cancer patients that the 
efficacies of LMWHs, UFH, and fondaparinux during 
initial VTE treatment were comparable [124]. 
During initial treatment of cancer patients with 
concomitant VTE not requiring thrombolytic therapy 
therapeutic doses of heparins (LMWHs, UFH) or fon-
daparinux are used. LMWHs are the most frequently 
used drugs during PE treatment in cancer patients, but 
only in patients with high risk PE therapy starts with 
infusion of UFH followed by thrombolytic treatment 
[75, 125–133]. 
The percentage of cancer patients in RCTs regard-
ing efficacy and safety of DOAC during initial treatment 
of VTE was low (< 10%), so those drugs should not 
be used in this phase of therapy in cancer patients with 
concomitant VTE. Unfractionated heparin is still the 
backbone drug in patients with clinically justified suspi-
cious or confirmed diagnosis of VTE. It should be used in 
optimal doses because it was shown that inadequate APTT 
prolongation (or insufficient increasing of anti-Xa activ-
ity) within the first 24 hours of treatment could increase 
VTE risk by even more than ten times [40]. On the other 
hand, it was also proven that administration of UFH in 
continuous infusion in total daily dose exceeding 30,000 or 
35,000 IU protects the patient against recurrence of VTE, 
regardless of APTT value. Fondaparinux is another drug 
used during the initial phase of VTE treatment. The 
MATISSE PE study [133] indicated that fondaparinux is 
safe and efficacious in patients with PE, similarly to UFH.
Abandonment of antithrombotic treatment (for 
many reasons, e.g. high bleeding risk) or overlooking the 
thrombus in angio-CT scans in patients with incidental 
VTE led to increased mortality [134]. 
ACCP guidelines recommend using of antithrom-
botic treatment in cancer patients with accidental diag-
nosis of DVT or PE [135].
Guidelines: 
1. Treatment of DVT or PE in cancer patients is similar 
to that used in non-cancer patients. 
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2. Cancer patients with concomitant DVT or PE, 
who do not require thrombolytic treatment, could 
be treated in outpatient settings, provided that 
the following conditions are fulfilled [39]: stable 
clinical patient’s state, adequate basic vital signs, 
low bleeding risk, serum creatinine concentration 
below 150 µmol/l or eGFR over 60 ml/min, ensured 
system of antithrombotic drugs administration and 
professional supervision by trained nurse or physi-
cian towards bleeding complications, efficacy of 
antithrombotic treatment, and recurrence of VTE.
3. Cancer patients with concomitant extensive, proximal 
DVT, or PE requiring either antithrombotic therapy 
or embolectomy should be treated in hospital set-
tings.
4. Every time, bleeding risk and potential benefits of 
antithrombotic treatment should be balanced. 
5. LMWHs given s.c. are recommended during initial 
treatment in the majority of cancer patients diag-
nosed with VTE (subunit 2.5.1) [1B].
6. During LMWH treatment, moderate patient activity 
is recommended [2C].
7. Patients with VTE are recommended to be mobilised 
with simultaneous using of pressure therapy (PUP, 
PESU — subunit 2.7), provided that there are no 
contraindications. Periodic control of local state and 
tolerability of pressure therapy is also recommended 
[2C].
8. In cancer patients with contraindications to LMWHs 
treatment with UFH (IV or s.c.) (subunit 2.5.2) or 
fondaparinux (subunit 2.5.3) is recommended [2C].
9. DOAC are not recommended during initial treat-
ment of cancer patients with concomitant VTE [2C].
10. Thrombolytic treatment (subunit 2.8) in cancer pa-
tients with concomitant DVT should be considered 
only in cases with massive limb-threatening changes 
in iliofemoral vessels. Good prognosis (expected 
survival time at least one year), low bleeding risk, 
and no contraindications to thrombolytic treatment 
are necessary conditions. Described management 
should be initiated no later than 14 days after onset of 
clinical symptoms [2C]. In the abovementioned case 
the drugs should be administered during 1–2 days in 
very low doses through a catheter inserted inside the 
thrombus. Systemic thrombolytic treatment could be 
used in specific situations, among others when the 
thrombolytic drug cannot be delivered inside the 
thrombus due to lack of an experienced treating team.
11. In patients with incidental VTE the management 
should be the same as during symptomatic VTE [2C].
5.2.	Initial	treatment	of	cancer	patients	with	PE	with	
need for thrombolytic therapy
UFH IV is recommended during initial treatment 
of this group of patients. In justified cases LMWHs 
could be considered. There are very few reports of us-
ing LMWHs in patients with PE requiring thrombolytic 
treatment but their results are quite encouraging.
In patients with shock induced by PE thrombolytic 
treatment should be introduced. However if it fails or 
could not be used, surgical embolectomy should be 
considered or transdermal treatment through catheter. 
Thrombolytic drugs should be used in patients with PE 
and concomitant shock or severe hypotension (preshock 
state is defined as decline of systolic blood pressure 
by 40 mm Hg during 15 minutes). In patients with 
cardiac arrest thrombolytic drugs could be difficult to 
administer. However, if a patient with cardiac arrest is 
in intensive care room and potential cause of this state 
could be PE, thrombolytic treatment during cardio-
pulmonary resuscitation could be possible. In patients 
with PE thrombolytic drugs should be administered to 
peripheral veins. It was not shown that administration 
of thrombolytic drugs directly to pulmonary artery im-
proves outcomes. 
Pulmonary embolectomy with extracorporeal cir-
culation in normo- or hypothermia is the basic surgical 
method of treatment of acute PE, with death risk of 
6% in experienced medical centers. It allows detailed 
assessment and removal of thrombotic tissue from the 
right ventricle, right atrium, as well as the pulmonary 
artery [136, 137].
In the subgroup of patients with absolute contrain-
dications to anticoagulation or after PE recurrence 
despite thrombolytic treatment, venous filters should 
be considered, which protect pulmonary circulation 
against in-flowing thrombi from deep veins of lower 
and upper extremities. Filters also reduce PE risk and 
subsequently cardiac arrest risk and death, but could ad-
ditionally increase the risk of post-thrombotic syndrome 
(PTS) [137, 138].
In all patients with PE requiring thrombolytic treat-
ment, adequate supportive care is needed.
Guidelines:
1. Initial treatment of cancer patients with concomitant 
PE requiring thrombolytic treatment or embolec-
tomy should be conducted in hospital settings [1C].
2. In patients with planned thrombolytic treatment 
UFH should be used as initial treatment (subunit 
2.5 and 5.1) [1C].
3. In treatment of cancer patients with PE during 
the first month of therapy and after stabilisation 
of patient’s state LMWHs are recommended and 
administered in therapeutic doses in two injections 
daily, which reduces the bleeding complication rate 
compared to administration of those drugs once daily 
only (subunit 2.5.1).
4. In cancer patients with concomitant high-risk PE, 
thrombolytic drugs are recommended (subunit 2.8), 
provided that there are no contraindications.
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5. Thrombolytic drugs are recommended to be ad-
ministered to peripheral veins but not to the pul-
monary artery.
6. When recombinant tissue plasminogen activators 
(rt-PAs) cannot be used in patients with PE and shock 
or hypotension, streptokinase should be introduced 
(subunit 2.8). After cessation of thrombolytic treat-
ment, UFH infusion should be initiated with an initial 
rate of 1000 IU/hour, continuing antithrombotic 
therapy according to general rules (subunit 2.5.2). 
7. Recurrence of PE requiring thrombolytic treatment 
in patients with previous SK treatment (between 
four days and nine months) is an indication to rt-PA 
(subunit 2.8).
8. In patients with cardiac arrest, possibly as a result of 
PE requiring thrombolytic treatment, a rt-PA bolus 
should be used (subunit 2.8). The advantage of an 
rt-PA bolus over two hours of SK therapy is based 
on possibly faster reduction of pulmonary resistance 
after rt-PA. 
9. 12-hour administration of thrombolytic drugs in 
cancer patients with concomitant PE is not recom-
mended because such long treatment duration is 
associated with unacceptable increase in bleeding 
rate in this group of patients. 
10. In patients with shock resulting from PE requiring 
thrombolytic treatment after failure of thrombolytic 
drugs, pulmonary embolectomy should be consid-
ered.
11. Indications to pulmonary embolectomy are as fol-
lows:
a. shock and massive obturation of pulmonary artery 
in patients with contraindications to thrombolytic 
treatment (early period after surgical procedure 
or intra-operative embolism); 
b. failure of thrombolytic treatment [21, 23]. 
12. In some cancer patients with concomitant PE, im-
plantation of inferior vena cava filter should be con-
sidered.
13. Indications to implantation of inferior vena cava filter 
are as follows:
a. initiating or continuation of PE causative treat-
ment is impossible due to contraindications or 
treatment complications;
b. PE treatment according general rules failed, with 
signs of PE recurrence;
c. status after embolectomy or planned thrombo-
endarterectomy without any contraindications 
to anticoagulation. 
14. Specific indications to implantation of retrievable 
inferior vena cava filter associated with PE risk 
could be considered in exceptional cases. It relates 
to patients with absolute contraindications to phar-
macological thrombolytic treatment, occurrence 
of complications after thrombolytic treatment, or 
failure of adequately conducted thrombolytic treat-
ment [23]. 
15. In all patients, adequate supportive therapy is neces-
sary, which very often has extreme importance for 
the patient’s further life: 
a. all patients with PE and with shock, significant 
decline of blood pressure, respiratory failure, 
significant overloading of right ventricle, or car-
diac arrhythmia need to be treated in intensive 
supervision units; 
b. in case of shock, invasive blood pressure monitor-
ing (haemodynamic line) is essential;
c. patients with acute respiratory distress should 
have adequate oxygen supply — in most cases na-
sal canola or mask precisely maintaining specific 
oxygen concentration in gas mixture is sufficient;
d. in case of advanced, acute disorders, therapy with 
techniques of non-invasive ventilation should be 
initiated, and in exceptional cases intubation and 
mechanical ventilation is indicated; 
e. in patients with hypotension or shock, catecho-
lamines should be administered. The treatment 
should be initiated with dopamine, and if it fails 
noradrenalin and dobutamine are used. 
5.3.	Long-term	and	chronic	treatment	of	cancer	
patients with VTE 
RCTs (LITE, CLOT, ONCENOX, CANTHA-
NOX) and meta-analyses indicate that LMWHs used 
in long-term treatment is associated with approx. 
50% reduction of VTE recurrence rate as compared 
to VKA administration with similar bleeding risk [46, 
118–124, 135]. The CLOT study was a breakthrough 
clinical trial, assessing the efficacy and safety of LM-
WHs in VTE treatment in cancer patients [123]. Can-
cer patients suffering from DVT and/or PE received 
dalteparin in the dose of 200 IU/kg b.w. once daily for 
5–7 days and VKA (to maintain INR between 2.0–3.0) 
or dalteparin in the dose of 200 IU/kg b.w. once daily 
during the first month, and then 150 IU/kg b.w. once 
daily during next five months. The probability of 
VTE recurrence during six months of follow-up was 
17% in the group receiving VKA and 9% in patients 
with long-term treatment with dalteparin [hazard 
ratio (HR) 0.48, P = 0.002]. There were no differ-
ences in major bleeding rates and mortality between 
both groups. Two other studies [121, 122] confirmed 
efficacy of enoxaparin and tinzaparin in the chronic 
treatment of VTE in cancer patients as compares 
to initial therapy with LMWHs followed by VKA. 
Systematic review and Cochrane analysis comparing 
efficacy of LMWHs and VKA in long-term treatment 
showed decreased VTE recurrence rate after LM-
WHs compared to patients receiving VKA (RR 0.49; 
83
Marek Z. Wojtukiewicz et al., Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients
95% CI 0.34–0.70) with similar bleeding rate [46]. 
Additionally, it was indicated that use of only full or 
medium but not prophylactic dose of LMWH shows 
advantages over VKA administration in prevention 
of VTE recurrences [121]. Furthermore, RTCs and 
meta-analyses showed the advantages of LMWHs 
over VKA in chronic treatment (up to six months) 
[46, 118–120].
Based on results of the LITE, CLOT, ONCENOX, 
and CANTHANOX studies on VTE treatment in cancer 
patients, it was noted that initial therapy with therapeutic 
doses of LMWHs should be prolonged up to at least one 
month, and then reduction of LMWH dose to 75–80% 
of baseline therapeutic dose should be consider or full 
doses of LMWH should be continued at least during the 
first three months of treatment [118–123]. 
Optimal duration of LMWHs treatment in cancer 
patients who experience DVT is still debatable. Contin-
uation of antithrombotic treatment beyond 3–6 months 
and the means of its administration should be taken 
individually, considering the risk of VTE recurrence 
and possible complications. The DALTECAN study, 
including 334 cancer patients with concomitant VTE, 
indicated that use of dalteparin for the first month in the 
dose of 200 IU/kg body weight (no more than 18,000 IU) 
and then its continuation for 2 to 12 months in the dose 
of 7,500 IU in patients with body weight not higher than 
56 kg, 10,000 IU in patients with body weight between 
56–68 kg, 15,000 IU in patients with body weight be-
tween 83–98 kg, and 18,000 IU in patients with body 
weight over 99 kg, was associated with low bleeding rate 
(10.2% of patients), but the highest bleeding risk was 
observed during the first month of antithrombotic treat-
ment [139]. VTE recurrences were reported in 11.1% 
of patients (5.7% during the first month, 1.34% during 
2–6 months, and 4.1% during 7–12 months). However, 
analysis of data from the RIETE database indicated 
that among 7,911 cancer patients (in active stage) un-
dergoing antithrombotic treatment for a mean period 
181 days (± 210 days) PE recurrences were observed 
in 178 patients and DVT recurrences in 194 patients, 
whilst in 367 patients bleedings were reported. Among 
4,125 patients with PE 45 patients died from PE recur-
rence, and 45 from bleeding. However, among 3,786 pa-
tients with previous DVT — 19 patients died from PE, 
and 55 patients dies due to bleeding [13].
Risk of VTE recurrence can be assessed according 
to the Louzada score (Table 4) [140].
Prolongation of LMWHs administration beyond six 
months in the treatment of first VTE episode in cancer 
patients should be considered in patients with stage IV 
malignant brain tumours, lung, ovarian, gastrointestinal 
cancer, with metastases to bone marrow and dysplasia 
of bone marrow, or with paresis of extremities and stage 
III neurological syndromes [141].
The beneficial influence of LMWHs on decreasing 
VTE recurrence rate is observed only during their ad-
ministration and does not transfer to the period after 
cessation of antithrombotic treatment [142]. The dura-
tion of chronic treatment depends on the presence of 
VTE risk factors and should last as long as they main-
tain. In some patients there is a consistently increased 
risk of VTE recurrence, suggesting some benefits from 
indefinite antithrombotic treatment, e.g. in the case of 
active cancer. In patients with transient risk factor (e.g. 
immobilisation) the risk of VTE recurrence decreases 
with time.
LMWHs and UFH are used in the treatment of 
cancer patients with VTE [24]. Administration of ASA 
is suggested after cessation of antithrombotic treatment, 
but there are very few data regarding such management 
in cancer patients [143, 144]. 
DOAC showed similar efficacy in VTE treatment 
as compared to standard therapy with heparin and then 
warfarin, as well as similar bleeding risk in subanalyses of 
large clinical studies with those drugs in VTE treatment 
[145]. However, these observations are based on studies 
with small sample sizes (cancer patients accounted for 
5% of the total group on average, and they were even 
excluded from some studies). There was no significant 
advantage of one DOAC drug over another in compara-
tive analyses of cancer patients. There are also available 
data suggesting lower VTE recurrence risk in cancer 
patients receiving DOAC in acute disease phase, as 
compare to standard treatment, most likely in connec-
tion with better stability of anticoagulation compared 
to warfarin, resulting from lack of diet influence and 
rare drug-drug interactions [146]. Malignant disease 
with high bleeding risk is a contraindication to DOAC 
treatment. Thus, based on observational studies DOAC 
could be a therapeutic option in cancer patients treated 
for VTE when other drugs, especially heparin, are not 
tolerated or are ineffective, or due to patient’s prefer-
ences, e.g. in patients with hypersensitivity to LMWHs 
or after HITT episode. Use of DOAC in cancer patients 
Table 4. The Louzada score for assessment of the risk 
of venous thromboembolism recurrence in cancer 
patients [140] 
Risk factor Score
Female gender 1
Lung cancer 1
Breast cancer –1
TNM, CS I –2
Previous VTE 1
Score: ≤ 0 — low recurrence risk; ≥ 1 — high recurrence risk
TNM — classification of cancer clinical stage (T — tumour, N — lymph node, 
M — metastases); CSI — clinical stage I
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is discouraged, especially in elderly patients, having 
higher bleeding risk. Major bleeding risk, mainly from 
the gastrointestinal tract, is a relative contraindication to 
DOAC because those drugs are active in the gastrointes-
tinal tract, which increases the risk of the complication 
as compared to other anticoagulants. Anticancer drugs 
metabolised through 3A4 cytochrome or transported 
by P-glycoprotein [bortezomib, cyclosporine, dexa-
methasone, most of tyrosine kinase inhibitors (TKIs), 
tamoxifen, some immunomodulatory drugs, sup-
portive drugs (e.g. fentanyl, methadone, clonazepam, 
ondansetron, aprepitant, and fosaprepitant)] intensify 
anticoagulation effects of DOAC and increase bleeding 
risk. Thereby, in this group of patients, measurement of 
blood drug concentrations could be very useful [147]. 
In Europe dabigatran is not recommended in patients 
treated with cyclosporine or tacrolimus — potent in-
hibitors of P-glycoprotein. Patients with eGFR below 
30 ml/min or worsening kidney functions should not 
be treated with DOAC to decrease major bleeding 
risk. eGFR monitoring 2–3 times yearly improves the 
safety of DOAC treatment. Periodical monitoring of 
liver function and complete blood count including 
platelet count is also recommended in patients treated 
with DOAC.
To date, treatment with DOAC was not assessed in 
RCTs in cancer patients suffering from VTE [148–151].
Guidelines:
1. LMWHs are preferred in long-term and chronic 
treatment of cancer patients with VTE over VKA 
[1A] or DOAC [2C].
2. Considering high VTE recurrence risk, initial 
therapy with therapeutic doses of LMWHs (subunit 
2.5.1) in cancer patients with VTE should be pro-
longed up to at least one month, and then reduction 
of LMWH dose to 75–80% of baseline therapeutic 
dose should be considered or full doses of LMWH 
should be continued at least during the first three 
months of treatment (long-term treatment) [1A].
3. DOAC should not be used in VTE treatment in 
cancer patients, unless other drugs cannot be used 
or they are insufficient or this decision is based on 
the patient’s preferences. 
4. Long-term antithrombotic therapy is recommended 
in cancer patients after PE. After one month of initial 
treatment chronic LMWH therapy should be contin-
ued for the next five months, with use of 75–80% of 
therapeutic dose (subunit 2.5.1). 
5. Beyond six months after past PE, treatment with 
LMWH could be continued if still indicated.
6. Drugs from the VKA group could be used as 
needed after six months of LMWH administration. 
Target INR values should be in the range between 
2.0–3.0 (subunit 2.5.4). 
7. In patients with PE complicated by chronic pul-
monary hypertension, chronic treatment should be 
administered for an indefinite period.
8. When there is no possibility to use, or there are 
contraindications to, long-term administration of 
LMWH in cancer patients VKA therapy is suggested 
as an alternative management (subunit 2.5.4) [1B].
9. In patients with active cancers, LMWHs or VKA 
could be chronically used, if not contraindicated, with 
periodical assessment towards the need to continue 
antithrombotic therapy (at least one per year) [2C].
10. Antithrombotic drugs should be administered until 
the patient’s recovery from cancer or until the end 
of life when the cancer is not curable. 
11. In patients with symptomatic thrombosis of mes-
enteric or hepatic veins antithrombotic treatment 
should be used, but in case of accidental diagnosis 
it is suggested not to initiate a therapy. 
12. Cancer infiltration of the pericardium requires that 
antithrombotic treatment be conducted with caution.
13. In patients with primary brain malignant tumours 
and concomitant VTE, antithrombotic treatment is 
recommended as in cancer of other localizations, but 
the patient should be monitored more frequently in 
order to avoid bleeding complications.
14. When paracentesis or other surgical procedures are 
planned in cancer patients treated with VKA, oral 
antithrombotic treatment should be interrupted and 
instead LMWHs should be used.
15. When VTE is diagnosed during anticancer non-sur-
gical treatment, chemotherapy and/or radiotherapy 
should be continued with concomitant administra-
tion of appropriate antithrombotic treatment in ad-
equate doses, unless there are any special conditions. 
16. In cancer patients with concomitant VTE requiring 
surgical operation the best decision would be to 
postpone the procedure by up to three months, but 
if impossible, implantation of a retrievable inferior 
vena cava filter could be considered, if VTE is pre-
sented as proximal DVT of lower extremities.
17. In breast cancer patients treated with tamoxifen with 
concomitant VTE it is recommended to replace this 
drug with an aromatase inhibitor, and then after ad-
ministration of LMWHs in full doses, continuation 
of treatment with 75–80% of baseline doses should 
be considered (subunit 2.5.1). 
18. In cancer patients with concomitant VTE during 
adjuvant chemotherapy after administration of LM-
WHs in full doses, continuation of treatment with 
75–80% of baseline doses for the next six months 
should be considered (subunit 2.5.1).
19. In cancer patients with CR after systemic cura-
tive treatment and with concomitant VTE during 
chemotherapy, after administration of LMWHs in 
full therapeutic doses, continuation of treatment with 
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75–80% of baseline doses for the next six months 
should be considered (subunit 2.5.1).
20. In cancer patients during palliative chemotherapy 
achieving CR, even in patients with high cancer re-
currence risk, the duration of chronic antithrombotic 
treatment should be discussed with patients on an 
individual basis.
21. In cancer patients with concomitant DVT (especially 
axillary vein and more proximal veins), antithrom-
botic treatment should be initiated as soon as possi-
ble; preferred drugs include LMWHs (subunit 2.5.1) 
and fondaparinux (subunit 2.5.3) administered for at 
least three months (if there is no central catheter) 
or continuously (when there is still an inserted cen-
tral catheter).
22. Some patients need thrombolytic drugs to maintain 
the central catheter in the vein (e.g. after symptoms 
intensification, when thrombus occludes the majority 
of the lumen of the subclavicular and axillary vein, 
symptoms sustain longer than 14 days, the patient is 
in good general state, expected survival time exceeds 
one year, and there is low bleeding risk). 
5.4. Treatment of cancer patients with VTE and 
concomitant thrombocytopaenia
Venous thromboembolism can sometimes develop 
in cancer patients with concomitant thrombocytopaenia 
[96]. In order to establish optimal management, the fol-
lowing should be identified: 
 — cause of thrombocytopaenia (cancer infiltration of 
bone marrow, effect of chemotherapy, immunologi-
cal thrombocytopaenia, drug-induced thrombocyto-
paenia, thrombotic microangiopathy, etc.);
 — severity of thrombocytopaenia (no signs of haemor-
rhagic diathesis vs. bleeding); 
 — expected duration time of thrombocytopaenia (tran-
sient vs. long-term); 
 — presence of additional (except thrombocytopaenia) 
risk factors of bleeding (older age, kidney and liver 
insufficiency, etc.).
The choice of antithrombotic treatment and its 
intensity in those cases should be based on individual 
assessment of potential benefits and disadvantages as-
sociated with the use of anticoagulants [13, 152–154]. 
Guidelines: 
1. Use of therapeutic doses of antithrombotic drugs 
is recommended without transfusion of platelet 
concentrate if platelet counts in cancer patients with 
acute VTE episode are ≥ 50 G/l and there are no 
symptoms of haemorrhagic diathesis [2C].
2.  In cases of acute VTE episodes in cancer patient 
with platelet count < 50 G/l but without symptoms 
of haemorrhagic diathesis:
a. use of therapeutic doses of antithrombotic 
drugs is recommended with transfusion of plate-
let concentrate in order to maintain platelet 
count ≥ 50 G/l. If it is impossible to maintain 
target platelet count, a decision about the use of 
therapeutic doses of antithrombotic drugs or their 
reduction should be based on individual assess-
ment of potential benefits and disadvantages of 
particular therapeutic options [2C];
b. if transfusion of platelet concentrate allows main-
tenance of platelet count in the range between 
20–50 G/l, it is suggested to reduce the doses of 
antithrombotic drugs to 50% of therapeutic dose, 
but in clinically justified cases maintenance of 
therapeutic doses could be favourable [2C]; 
c. if platelet count drops below 20 G/l despite trans-
fusion of platelet concentrate, it is suggested to 
withdraw antithrombotic drugs [100] [2C].
3. In patients with limited clinical symptoms of haemor-
rhagic diathesis, without tendency to intensify during 
antithrombotic treatment, the above guidelines do 
not have to be modified.
4. In cases of acute VTE episodes in cancer patients 
with concomitant thrombocytopaenia and symp-
toms of haemorrhagic diathesis, it is suggested not 
to use antithrombotic drugs; however, the final 
decision should be based on individual assessment 
of potential benefits and disadvantages resulting 
from antithrombotic treatment or its discontinu-
ation.
5. If transfusion of platelet concentrate is impossi-
ble or contraindicated and if there are significant 
clinical symptoms of haemorrhagic diathesis and 
acute episode of DVT of lower extremities could 
be life-threatening, implantation of a retrievable 
inferior vena cava filter should be considered in 
order to prevent PE. After resolution of contrain-
dications to antithrombotic treatment the filter 
should immediately be removed and appropriate 
doses of antithrombotic drugs should be introduced. 
Literature data show that implantation of an infe-
rior vena cava filter could cause poorer long-term 
prognosis (e.g. more frequent DVT recurrences) 
as compared to patients with VTE without filter 
implantation (these data are also relevant to cancer 
patients) [155–157]).
6. In the chronic treatment of cancer patients with con-
comitant thrombocytopaenia and VTE the following 
is suggested:
a. reduction of LMWHs doses by 50%, if platelet 
count is in the range 25–50 G/l and there are no 
bleedings; 
b. cessation of antithrombotic treatment if platelet 
count is < 25 G/l and/or there are significant 
symptoms of haemorrhagic diathesis [2C].
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5.5. Treatment of cancer patients with VTE and 
renal	insufficiency	
The risk of bleeding complications in patients with 
renal insufficiency resulted from the use of therapeutic 
doses of LMWHs administered s.c. is two-fold higher as 
compare to patients with normal renal function [158]. 
There is a lack of data regarding accumulation of 
dalteparin. RCTs assessing the efficacy and safety of 
VTE treatment with DOAC included only 2.6–10% of 
cancer patients, and patients with eGFR < 50 ml/min 
accounted for only 7–21% of patients analysed in those 
trials. Elimination of DOAC through the kidneys is 
in the range between 80% (dabigatran) and 25% 
(apixaban); however, for rivaroxaban and edoxaban 
they are 33% and 35%, respectively [159]. The use-
fulness of DOAC in the prevention and treatment 
of cancer patients with VTE and renal insufficiency 
was not assessed to date in RCTs. Guidelines regard-
ing ESC in PE patients allows for the use of DOAC 
in eGFR > 30 ml/min if the bleeding risk in cancer 
patients is not high, which is associated with chronic 
treatment of VTE in patients with good prognosis. The 
majority of experts consider treatment with DOAC in 
cancer patients and renal insufficiency as not indicated 
[8, 104, 153]. Nevertheless, this is possible in carefully 
selected patients.
Renal insufficiency significantly increases the risk of 
VTE recurrence in cancer patients receiving antithrom-
botic drugs. In the CATCH study VTE recurrence dur-
ing the first six months was detected in 14% of patients 
with eGFR < 60 ml/min but only 8% in the remaining 
patients [160].
Guidelines [23, 104, 105, 153, 161, 162]: 
1. In the initial treatment of cancer patients with VTE 
and renal insufficiency it is suggested to use intrave-
nous UFH in therapeutic doses for 5–10 days with 
monitoring of APTT, which should be prolonged 
1.5–2.5-fold as compare to baseline value. VKA could 
be introduced already on the first day together with 
UFH withdrawal, provided that INR is > 2 for two 
consecutive days [2C].
2. Treatment with LMWHs with monitoring of anti-Xa 
activity could be an alternative option; however, 
optimal therapeutic concentration of LMWHs in 
this group of patients was not established to date. 
In patients without renal insufficiency treated with 
LMWHs, anti-Xa activity four hours after LMWH 
injection should account for 0.6–1.0 IU/ml during 
administration every 12 hours and 1.0–1.5 IU/ml 
during administration every 24 hours. Another op-
tion for patients treated with therapeutic doses of 
LMWHs and with eGFR < 30 ml/min is reduction 
of standard LMWH dose by 50% [2C].
3. In patients with end-stage renal disease during acute 
phase of VTE extracorporeal haemodialysis could be 
used in order to increase the safety of antithrombotic 
treatment. Indications to this procedure as well as 
doses of LMWH need to be established individually.
4. DOAC can be recommended only in selected cancer 
patients, with eGFR > 15 ml/min (minimal value for 
treatment with apixaban or rivaroxaban according 
to manufacturer’s information), eGFR > 30 ml/min 
(minimal value for treatment with dabigatran), when 
administration of nephrotoxic drugs or drugs strongly 
influencing activity of cytochrome P450 (3A4) isoen-
zyme and P-glycoprotein is not planned, with exclu-
sion of patients with intracranial tumour or tumour 
in other locations with bleeding risk, and in patients 
with thrombocytopaenia or liver injury [2C].
5. The decision about initiation of antithrombotic 
treatment in cancer patients with renal insufficiency 
needs to be individually assessed because there is 
increased risk of bleeding complications; however, 
in life-threatening situations, e.g. in patients with 
PE of high death risk, this indication is considered 
as relative.
6. In order to prevent recurrences it is recommended 
to use LMWHs for 3–6 months, and then VKA or 
LMWHs chronically or until cancer resolution [2C].
5.6. Treatment of pregnant women with 
coincidence of cancer and VTE
In pregnant women with cancer and coincident 
VTE initial treatment is mainly based on LMWHs and 
UFH, which do not cross the placenta. Fondaparinux 
is not registered for the treatment during pregnancy, 
but during in vitro studies on experimental models it 
was indicated that it also does not cross the placenta 
[163]. The duration of VTE initial treatment is most 
commonly 5–7 days, but in selected cases, e.g. extensive 
thrombosis in iliofemoral part, prolongation of therapy 
up to two weeks could be considered (see below). Dosing 
of LMWHs and UFH during initial VTE treatment in 
pregnant women does not differ from treatment of other 
patient populations. In patients with renal insufficiency, 
in obese women, and in case of doubts regarding the ef-
ficacy and safety of LMWHs during pregnancy, serum 
anti-Xa activity should be measured four hours after 
last injection of the drug. When injections of therapeu-
tic doses of LMWHs are administered every 12 hours 
the therapeutic value of anti-Xa should be within the 
range 0.6–1.0 IU/ml, but when injected every 24 hours 
— 1.0–1.5 IU/ml [164, 165]. Anti-Xa activity should 
also be assessed before the next dose of LMWH; this is 
recommended in pregnant women with prosthetic heart 
valve, but could also be helpful in suspicion of standard 
dose failure.
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Chronic treatment of pregnant women with cancer 
and after VTE episode should include UFH or LMWHs 
administered until the end of pregnancy and at least 
six weeks after the labour, altogether not shorter than 
six months. The daily dose of LMWHs in those cases 
should not be lower than 50% of the therapeutic dose. 
Some authors recommend continuation of LMWHs 
administered in therapeutic doses with anti-Xa activity 
measured every 1–3 months until the end of pregnancy. 
VKA are contraindicated during pregnancy; however, 
they could be used after giving birth by breast-feeding 
women as they are not excreted into human milk. 
In order to reduce bleeding risk during delivery 
the last therapeutic dose of LMWH or UFH should 
be injected no later than 24–36 hours before planned 
induction of labour [101, 102]. Infusion of UFH should 
be finished 4–6 hours before planned delivery. If labour 
spontaneously starts during the full anticoagulation pe-
riod central anaesthesia should be abandoned. In case 
of bleeding complications protamine sulphate should 
be used, which shows very high efficacy in reverse an-
tithrombotic UFH effect, but significantly more weakly 
inhibits LMWHs. It should be also underlined that 
caesarean section increases the risk of VTE episode 
by two-fold as compare to natural delivery [164, 165]. 
LMWHs should be restarted 12–24 hours after deliv-
ery and at least 12 hours after removal of the catheter 
for central anaesthesia, provided there are no bleed-
ing complications.
Indications to thrombolytic treatment in pregnant 
women are the same as in other patients with acute VTE 
episode. Pregnancy is only a relative contraindication to 
thrombolysis in high-risk PE. Some clinicians consider 
that thrombolytic drugs could lead to placental abrup-
tion; however, there are no publications in scientific 
literature confirming this opinion [165].
Other methods of treatment of pregnant women 
with cancer and acute VTE episode include venous 
thrombectomy, implantation of an inferior vena cava 
filter in order to prevent PE, and embolectomy of pul-
monary artery. Indications to the mentioned procedures 
in pregnant women do not differ from indications in 
other groups of patients. 
Guidelines:
1. Treatment of pregnant women with cancer and VTE 
should be conducted according the same rules as in 
other groups of patients [2C].
2. Both LMWHs and UFH can be used during preg-
nancy [2C]. 
3. VKA use is absolutely contraindicated during the 
first trimester of pregnancy and relatively contrain-
dicated and discouraged during the second and third 
trimesters of pregnancy (except in women after 
implantation of a prosthetic heart valve) [2C].
4. Dosing of LMWHs and UFH during initial and 
chronic treatment of pregnant women with cancer 
and concomitant VTE is similar to dosing of those 
drugs in other groups of cancer patients and VTE. 
Measurement of anti-Xa activity is used for laboratory 
monitoring of therapeutic doses of LMWHs [2C].
5. Fondaparinux is allowed in pregnant women with 
HITT [2C].
6. Dosing of LMWHs and UFH has to be appropriately 
modified during delivery to minimise the risk of 
bleeding complications.
7. UFH, LMWHs, or VKA could be used during child-
bed (they are not excreted into human milk), but 
their choice is based on the clinical situation (e.g. 
modality of anticancer therapy) and the patient’s 
preferences (influence of treatment on health-re-
lated quality of life, e.g. resulting from the need for 
frequent subcutaneous injections) [2C].
5.7.	Treatment	of	recurrent	VTE	during	
antithrombotic treatment
Cancer patients receiving antithrombotic treat-
ment also quite often have relapses of VTE [168–171]. 
However, there is lack of strong evidence allowing de-
velopment of the guidelines. Cancer patients with VTE 
recurrence undergoing optimal antithrombotic treat-
ment should be evaluated towards potential progression 
of malignant disease. In patients receiving LMWHs or 
UFH within the last 10–14 days it is also important to 
exclude HITT. Medical history regarding the patient’s 
compliance and rigid taking of antithrombotic drugs 
should also be taken.
Guidelines:
1. In the case of VTE recurrence during treatment with 
LMWHs their dose could be increased by 20–25% 
IU/ml using measurement of maximal anti-Xa activ-
ity (1.6–2.0 IU/ml during administration once daily, 
0.8–1.0 IU/ml during administration twice daily), or 
fondaparinux therapy could be considered — longer 
than three months (in case of low or moderate bleeding 
risk) and up to three months when bleeding risk is high.
2. In case of VTE recurrence during VKA administra-
tion it is suggested to replace them with LMWHs or 
UFH s.c. (APTT 1.5–2.5 × control value).
6. Using of antithrombotic treatment 
in order to prolong overall survival in 
cancer patients
Available evidence from clinical trials does not 
justify use of antithrombotic drugs to prolong survival 
in cancer patients.
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